A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study

Area of Science:

• Nephrology
• Diabetology
• Hematology

Background:

• Diabetic nephropathy is a leading cause of kidney disease.
• Platelets are implicated in the progression of diabetic nephropathy.
• Platelet aggregation inhibitors may offer a therapeutic benefit.

Purpose of the Study:

• To investigate the effect of ticlopidine on renal function decline in diabetic nephropathy.
• To assess if ticlopidine can prevent or slow kidney function deterioration in diabetic patients.

Main Methods:

• A randomized, double-blind, placebo-controlled trial.
• Twenty-two patients with insulin-dependent diabetes and nephropathy were enrolled.
• Patients received either ticlopidine or placebo for one year.

Main Results:

• Ticlopidine effectively reduced platelet aggregation in vitro.
• Renal clearance (51Cr-EDTA) declined in both groups, with no significant difference between ticlopidine and placebo.
• Renal function, measured by 1/S-creatinine slope, remained stable in the ticlopidine group compared to pre-trial levels.

Conclusions:

• Ticlopidine treatment did not prevent the decline in renal function in patients with diabetic nephropathy.
• Despite evidence suggesting a role for platelets, ticlopidine was ineffective in this trial.
• Further research may be needed to explore other antiplatelet strategies or mechanisms.